Treating T3 Deficiency, The Evidence You Need Part 4

Register Now - $40

DURATION:
1 Hour
CREDIT:
1 AMA PRA Category 1 Creditâ„¢
1 Nursing Contact Hour (1 Pharmacologic Hour)

INSTRUCTORS:

Neal Rouzier, MD
Faculty Chairman

Categories

1 Hour Courses

This course is included in Upgraded Memberships. Upgrade your Membership now >

Course Description:

During this month’s webinar, Dr. Rouzier will be reviewing the controversial literature that does not recommend giving thyroid hormone to patients with SCH when their TSH is less than 20.  Why the authors came to this conclusion and how these guidelines can impact the quality of life for many patients.  Some current research studies support giving DTE to alleviate symptoms and decrease C-IMT along with improved lipid profiles for these patients.  Dr. Rouzier will also be discussing how T3 can be beneficial in improving mood and energy levels for depressed patients.

Objectives:

Upon completion of this workshop, the healthcare professional will be able to:

  1. Discuss the current recommendations against using T4 monotherapy for SCH due to lack of efficacy in most studies.
  2. Identify why the panel recommended against hormone therapy due to no important benefits of treatment and the possibility of harm.
  3. Review the studies demonstrating a low Free T3 level being responsible for symptomology and CVD.
  4. Review studies demonstrating improvement in symptoms with DTE as well as improvement in Free T3 levels with T3 and DTE, but not T4 monotherapy.
  5. Recall how combination therapy may be controversial but how physicians may prescribe it to improve adherence to treatment and patient well-being.
  6. Define the physiology behind lack of improvement with T4 monotherapy and the appropriate therapy to avoid the lack of efficacy of T4 monotherapy.
  7. Review the multiple studies demonstrating improvement in lipid parameters and a decrease in CIMT with thyroid administration.
  8. Evaluate the recommendations of recent authors and papers that subclinical hypothyroidism should not be treated.  Lack of clinical benefit with thyroxine monotherapy and a lifelong burden of taking a medicine that does not work are discussed.